Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6809 - 6816 of 12092 results
Massachusetts Receives Nearly Four Dozen Bids in Response to Request for Proposals for Renewable Energy Generation
August 25, 2017| Blog| Viewpoint
Massachusetts Moves Forward with Efforts to Shore up MassHealth
August 24, 2017| Blog| Viewpoint
Implied False Certification Theory Fails in FCA Case Against Billing Agent
August 23, 2017| Blog| Viewpoint
The Four Things That Surprised Us in the EpiPen False Claims Settlement
August 23, 2017| Blog| Viewpoint
In a Reversal, Federal Circuit Finds Data Processing Claims Patent-Eligible Under Section 101 in Visual Memory v. NVIDIA
August 23, 2017| Blog| Viewpoint
Medicare to Narrow Scope of Health-Care Provider Audits
August 23, 2017| News
The Wells Fargo PII Epic Fail - Chapter II
August 22, 2017| Blog| Viewpoint
U.S. Mission in Russia to Temporarily Suspend NIV Issuance
August 22, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|